Caterpillar To Butterfly? Ablynx Says Caplacizumab Data Transformational

 
• By Sten Stovall

Belgian Nanobody drug developer Ablynx says it will be transformed by positive Phase III topline HERCULES data on caplacizumab for treating the rare blood-clotting disorder, acquired TTP.

Butterfly
Caplacizumab could transform Ablynx into commercial drug company • Source: Shutterstock

More from Clinical Trials

More from R&D